trial

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

NCTId NCT01720316
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 2 (actual)
Sponsored by Mclean Hospital
Primary completion 2017-05-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
2 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2012-12-10
Primary completion
2017-05-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
glycine

Sponsors

Mclean HospitalLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Deborah L Levy, PhDPrincipal Investigator

Sites

1 total
Belmont, United States

Linked catalysts

1
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders — primary completion2017-05-31

Facts & assertions

4 sourced
Enrollment
2
Phase
PHASE2
Primary Completion Date
2017-05-31
Status
COMPLETED
relationships
The graph out of here
drug
glycine
drug
lead_sponsor
Mclean Hospital
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Bipolar Disorder
indication
Schizo-affective Disorder
indication
Hyperglycinemia, Nonketotic
indication
investigator
Deborah L Levy, PhD
person